Study Purpose: The purpose of this study is to look at how much a new investigational medicine called CagriSema lowers blood sugar and body weight in people with type 2 diabetes compared to another type 2 diabetes medicine called tirzepatide. We will compare CagriSema and tirzepatide and see how much they help people with type 2 diabetes to control their blood sugar and lose weight.

To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the following criteria:

Study Duration: Approximately 18 months

Study Commitment: 15 in-person visits | 7 follow-up phone calls

Age: 18+

Sex: Male & Female

Conditions/Eligibility:

-Must have a diagnosis of type 2 diabetes for at least 180 days (~6 months) at screening.

-Taking metformin only or metformin and SGLT2 inhibitor to treat type 2 diabetes.

-Must have a BMI (body mass index) of 30 or higher

-No personal history of unstable diabetic retinopathy

-No planned weight loss surgery

-No history of chronic pancreatitis

Study Procedures:

-Dilated eye exam

-Vitals and ECG measurements

-Blood and urine sampling (some of them require an overnight fast)

-Physical examination

-Once weekly dosing with study medication using an injection pen

-Questionnaires (clinical outcome assessments) completed on a study app

Compensation: $1850